Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|December 4, 2020

Lurbinectedin: NCCN Guidelines

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

FDA approval | Image Credit: Tada Images - stock.adobe.com .jpeg

5 Key Regulatory Shifts From Makary's Era at the FDA

ByPearl Steinzor

May 13th 2026

Marking 10 years since the CDC’s opioid prescribing guidelines, the 2022 update broadens patient care, emphasizes individualized decisions, and aims to reduce opioid-related harms. | Imaged credit: Tada Images - stock.adobe.com

The 10th Anniversary of the CDC's Opioid Prescribing Guidelines: New Evidence and Patient-Centered Decisions

BySabrina McCrear

March 24th 2026

Version 1.2026 of the guidelines emphasizes the necessity of multidisciplinary consultation at centers with specialized expertise for both high-risk and very-high-risk disease. | Image credit: wavebreak3 - stock.adobe.com

Guideline Updates Refine Management for Very High-Risk Squamous Cell Skin Cancer

February 27th 2026

Image credit: Parilov - stock.adobe.com

Disparities in Cervical Cancer Screening, HPV Awareness, Guidance Nonadherence Are Increasing

ByGiuliana Grossi

December 10th 2025

ROS1-positive NSCLC is aggressive and rare, with approximately 3000 new diagnoses of advanced disease in the US each year. | Image credit: appledesign - stock.adobe.com

Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC

July 31st 2025

Trending on AJMC

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

5 FAQs: Ebola Outbreaks and the Challenge of Public Trust

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD